Corporate ActionJun 23, 2026, 11:09 PM
MoonLake Immunotherapeutics Prices $200M Public Offering
AI Summary
MoonLake Immunotherapeutics announced the pricing of an underwritten public offering, expecting to raise approximately $200 million in gross proceeds. The offering includes 9,000,000 Class A ordinary shares at $20.00 per share and pre-funded warrants for 1,000,000 shares at $19.9999 per warrant. The company has also granted underwriters an option to purchase an additional 1,500,000 shares. Proceeds will be used to fund the research, development, and commercialization of sonelokimab, if approved, and for general corporate purposes.
Key Highlights
- Priced underwritten public offering of 9,000,000 Class A ordinary shares.
- Public offering price per share of $20.00.
- Offered pre-funded warrants for 1,000,000 Class A ordinary shares at $19.9999 per warrant.
- Gross proceeds expected to be approximately $200 million.
- Underwriters have 30-day option to purchase up to an additional 1,500,000 shares.
- Net proceeds to fund R&D, pre-commercialization, and commercialization of sonelokimab.
Price Impact
More from MLTX